A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
This study is testing two different drug combinations to see which works better in treating melanoma skin cancer that has spread to the brain. Researchers want to find the most effective way to shrink and control these brain tumors using targeted therapies and immunotherapies.
You might be eligible if you have a confirmed diagnosis of melanoma with a specific genetic mutation called BRAF-V600, and the cancer has spread to your brain. The study is open to adults who meet specific health and prior treatment guidelines, but those with eye melanoma or certain recent brain radiation are not eligible.
Participants will be randomly assigned to receive one of two treatment groups combining targeted drugs and immunotherapies to help fight the cancer. You will have regular check-ups and brain scans to monitor how well the treatment is working against the tumors.
This study is currently recruiting participants at multiple locations in Alabama, United States. Your care team will guide you through the specific clinic visits needed for your treatment and follow-up care.
- 1Compares two treatment approaches for melanoma that has spread to the brain
- 2Requires a specific genetic mutation called BRAF-V600
- 3Currently recruiting participants at locations in Alabama
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.